TBIO - トランスジェノミック (Translate Bio Inc.)

TBIOのニュース

   Translate Bio's mRNA Therapeutic For Respiratory Tract Infections Shows Promise In Animal Studies  2021/05/18 18:40:59 Benzinga
Translate Bio Inc (NASDAQ: TBIO ) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Mutations in the genes that cause PCD result in ineffective mucociliary clearance, which can lead to lung disease. The data were presented at … Full story available on Benzinga.com
   Leerink Partners Stick to Their Hold Rating for Translate Bio Inc By Investing.com  2021/05/10 12:27:28 Investing.com
Leerink Partners Stick to Their Hold Rating for Translate Bio Inc
   Evercore ISI Stick to Their Hold Rating for Translate Bio Inc By Investing.com  2021/05/09 10:10:30 Investing.com
Evercore ISI Stick to Their Hold Rating for Translate Bio Inc
   Translate Bio Inc $TBIO: Cash per share is equal to $4.67, and the stock price is $17.525!  2021/03/18 15:26:51 StockMarketRevolution
With 73 million shares outstanding, at $17.525 per share, the market capitalization of Translate Bio Inc (TBIO) is equal to
   Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies  2020/08/25 19:13:53 Reuters
Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.
   Translate Bio Inc $TBIO: Cash per share is equal to $4.67, and the stock price is $17.525!  2021/03/18 15:26:51 StockMarketRevolution
With 73 million shares outstanding, at $17.525 per share, the market capitalization of Translate Bio Inc (TBIO) is equal to
   Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies  2020/08/25 19:13:53 Reuters
Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm  2020/07/31 20:55:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $TBIO #TBIO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc.
   The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week  2020/06/28 18:23:19 Benzinga
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel that could help them be successful in their quest. Translate Bio Inc (NASDAQ: TBIO ) rallied strongly earlier in the week on the back of news concerning an expansion of its vaccine development partnership with Sanofi SA (NASDAQ: SNY ) but eventually gave back some of the gains following a secondary offering. Vaxart Inc (NASDAQ: VXRT ), another COVID-19 vaccine play , rallied during the week. The FDA review machinery worked overtime, ruling on a host of investigational therapies. Three biopharma companies went public this week, raising a combined $485 million in gross proceeds. The following are key catalysts in the unfolding week: Conferences Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19: Tuesday, June …
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies  2020/08/25 19:13:53 Reuters
Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.
   INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm  2020/07/31 20:55:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $TBIO #TBIO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc.
   The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week  2020/06/28 18:23:19 Benzinga
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel that could help them be successful in their quest. Translate Bio Inc (NASDAQ: TBIO ) rallied strongly earlier in the week on the back of news concerning an expansion of its vaccine development partnership with Sanofi SA (NASDAQ: SNY ) but eventually gave back some of the gains following a secondary offering. Vaxart Inc (NASDAQ: VXRT ), another COVID-19 vaccine play , rallied during the week. The FDA review machinery worked overtime, ruling on a host of investigational therapies. Three biopharma companies went public this week, raising a combined $485 million in gross proceeds. The following are key catalysts in the unfolding week: Conferences Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19: Tuesday, June …
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Sanofi Accelerates Coronavirus Vaccine Timeline, Says Approval Could Come In First Half Of 2021  2020/06/23 17:42:36 Benzinga Feeds
Sanofi SA (NASDAQ: SNY ), which is in the race to develop a vaccine for SARS-CoV-2, which causes COVID-19, is unveiling an accelerated timeline for the vaccine program it is pursuing with GlaxoSmithKline plc (NYSE: GSK ). Sanofi has also expanded its collaboration with mRNA vaccine company Translate Bio Inc (NASDAQ: TBIO ). Sanofi Moves Up Vaccine Rollout Timeline: Sanofi said it expects to begin a Phase 1/2 study of the recombinant protein vaccine candidate it is co-developing with GlaxoSmithKline in September, and full approval is likely … Full story available on Benzinga.com

calendar